Rheonix, Inc., a developer of automated molecular testing solutions, and biotechnology company Life Technologies Corp. have entered into a joint development agreement to introduce a molecular testing platform. Technology developed by Rheonix for the molecular diagnostics market, including the Rheonix CARD, a disposable cartridge that can run multiple samples simultaneously without user intervention, will be supplied by Rheonix to Life Technologies for marketing, sales, and distribution.
The instrument and consumable cartridges are components of a molecular detection system specifically designed for the food testing market that will enable laboratories to detect disease-causing organisms, including serotype identification, in a fully automated and highly efficient manner. The new platform is targeted for initial introduction in 2014.
Rheonix spokespersons say that the company’s automated platform addresses the most difficult challenges facing the healthcare industry today, including workforce shortages, limited access to advanced molecular testing, and escalating costs. Once a raw sample is placed on the Rheonix CARD, they stress, the platform runs with no user intervention through the process of sample extraction, DNA purification, amplification, and detection. This eliminates the need for multiple pieces of existing equipment, helping make the testing process quicker, more efficient, less expensive, and less likely to result in human error. Learn more about Rheonix and Life Technologies.
